PDCD1 and myeloid sarcoma: Due to the heterogeneity of disease course and therapeutic responses in different patients with MS, the best intervention timepoint, the feasible combination therapeutics regimens and selective patients who may benefit from PD-1/PD-L1-based therapies should be confirmed to achieve an optimized therapeutic outcome.